RJA
HUMA icon

Raymond James & Associates’s Humacyte HUMA Stock Holding History

Raymond James & Associates’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$235K Buy
+43,278
New +$285K ﹤0.01% 3544
2023
Q2 		– Sell
-19,411
Closed -$60K – 3895
2023
Q1 		$60K Buy
+19,411
New +$55.2K ﹤0.01% 3717

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Raymond James & Associates's HUMA Position: Q3 2024 in Review

Raymond James & Associates opened a new position in Humacyte (HUMA) in Q3 2024: 43,278 shares worth $235K. The stake represents ﹤0.01% of the portfolio and ranks #3544 among its holdings. This is a return to the name: Raymond James & Associates previously reported a position in HUMA as recently as Q1 2023.

Raymond James & Associates first reported a position in HUMA in Q1 2023 and has held it in 2 quarters since. 143 funds tracked by Wall St. Rank hold HUMA as of Q3 2024.

  • Raymond James & Associates held 43,278 shares of Humacyte worth $235K as of Q3 2024.
  • Humacyte was a new Raymond James & Associates position in Q3 2024.
  • Humacyte made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3544 holding.
  • Raymond James & Associates first reported a position in Humacyte in Q1 2023 and has held it in 2 quarters since.
  • 143 funds tracked by Wall St. Rank held Humacyte as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.